Guideline-directed medical therapy (GDMT) for heart failure (HF) reduces major adverse cardiovascular events (MACE), including cardiac death and HF hospitalization. However, whether comorbidities influence GDMT effectiveness and dose optimization remains unclear.
To determine whether the association betwee...
S. Higuchi, Y. Shiraishi, T. Kohno et al.· European Heart Journal· 0 citations
Introduction:
Residual pulmonary hypertension (PH) after stabilization from acute decompensated heart failure (ADHF) is common and reflects heterogeneous pathophysiological mechanisms, involving left-sided filling pressures, pulmonary vascular remodeling, right-sided dysfunction, and comorbidity burden. Such heterog...
T. Iwanaga, Y. Shiraishi, S. Kohsaka et al.· Circulation· 0 citations
Sudden cardiac death (SCD) remains a major cause of mortality in patients with heart failure (HF) despite advances in medical and device therapy. Risk stratification relies largely on left ventricular ejection fraction (LVEF), yet many SCD events occur outside conventional implantable cardioverter-defibrillator (...
T. Tamura, Y. Shiraishi, S. Kosaka et al.· European Heart Journal· 0 citations
BACKGROUND
Guideline-directed medical therapy (GDMT) improves prognosis in heart failure (HF), but its implementation remains suboptimal, particularly in patients with multiple risk domains.
METHODS
We analyzed the association between GDMT achievement and the 2-year composite endpoint of cardiac death or HF hospitali...
S. Higuchi, Y. Shiraishi, Takashi Kohno et al.· American Journal of Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.